Isolation and Characterization of Anticancer Compound Producing Marine Paenibacillus lentimorbus SAGM 3 Collected from a Sea Anemone, Heteractis species

Sea anemone-associated bacteria were considered promising candidates for the synthesis of many novel bioactive compounds. Thus culturable symbiotic bacteria that exist in the sea anemones met much attention when compared to other benthic marine dwellers. In this study, an attempt was made to explore the anticancer potentials of symbiotic bacteria isolated from a sea anemone, Heteractis species. Nine symbiotic bacteria were isolated, pure cultured and screened for their anticancer potential using two breast cancer cell lines. Among the strains, SAGM 3 showed appreciable growth inhibition activity of 43.1% and 47.1% against the studied cell lines, viz. MCF7 and MDA-MB-231 and this strain was selected for further studies. Based on the 16S rRNA molecular profiling, the SAGM 3 isolate was noted as Paenibacillus lentimorbus and the sequence of SAGM 3 was deposited in GeneBank with the accession number MW737456.1. During the growth kinetics profiling, maximum bacterial growth rate and anticancer activities were recorded from 60 to 96 hrs of incubation. The present investigation provides baseline data understanding the pharmaceutical significance of a symbiotic marine bacterium procured from the sea anemone, Heteractis species.